Tonix Pharma +12% premarket on bullish call

• SA author Jeff Eiseman says shares could be worth anywhere from $54 to $225, and thinks other (bullish) analysts aren't bullish enough.
• Source: Tonix Pharmaceuticals: Four Data-Based Valuations Of A Deeply Underappreciated Pharmaceutical Company
• Jason Napodano, who also covers the stock, thinks Eiseman's estimates are "wildly too high." He has a $14 target on TNXP.
• Shares are up 12% premarket on light turnover of 17K.